生脉胶囊、双歧三联活菌胶囊联合马来酸曲美布汀治疗腹泻型肠易激综合征的效果

Effect of Shengmai Capsule、Bifid.Triple Viable and Trimebutine Maleate on Patients with Diarrehea-Predominant Irritable Bowel Syndrome

目的观察生脉胶囊、双歧三联活菌、马来酸曲美布汀三药联合治疗腹泻型肠易激综合征患者的效果。方法选取2017年1月至2019年6月盐城市大丰人民医院门诊就诊的腹泻型肠易激综合征患者70例,根据患者来院就诊时间先后分为观察组与对照组,各35例。对照组患者采用双歧三联活菌、马来酸曲美布汀双药联合治疗,观察组患者在此基础上联合生脉胶囊。比较两组治疗效果及不良反应发生率。结果治疗后,观察组患者治疗总有效明显高于对照组(97.14%vs.74.29%,P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论腹泻型肠易激综合征患者采用生脉胶囊、双歧三联活菌、马来酸曲美布汀三药联合治疗效果更佳,且安全性高,值得临床运用。

Objective To observe the effect of combined therapy of Shengmai Capsule,Bifid.triple viable and trimebutine maleate on patients with diarrehea-predominant irritable bowel syndrome(IBS-D).Methods A total of 70 patients with IBS-D admitted to Yancheng Dafeng People's Hospital from January 2017 to June 2019 were divided into an observation group and a control group according to the admission time,35 cases per group.The patients in the control group were treated with Bifid.triple viable and trimebutine maleate.The patients in the observation group were treated with Shengmai Capsule on the basis of control group.The therapeutic effects and incidences of adverse reactions were compared between the two groups.Results After treatment,the total therapeutic effect of the observation group was significantly higher than that of the control group(97.14%vs.74.29%,P<0.05).There was no significant difference in the incidences of adverse reactions after medication between the two groups(P>0.05).Conclusion The combined therapy of Shengmai Capsule,Bifid.triple viable and trimebutine maleate was effective and safe for patients with IBS-D,which is worthy of clinical application.